coteauBeta Get App

RAPP

Rapport Therapeutics, Inc.
$26.34
-10.32% Oct 21 close
Healthcare CompareTechnicals
-8%+19%+45%+72%+99%Oct 2025Oct 2026Apr 2026
RAPPSPY
1W
-7.0%
1M
-33.6%
3M
-36.3%
6M
-28.4%
YTD
-13.2%
1Y
-1.6%

Live chart

Loading live chart…

What they do

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for RAPP yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
Coteau Long Book
Not in the current book

News

More news
Rapport Therapeutics Enters Oversold Territory (RAPP)
Nasdaq · Oct 21

Key stats

Market value$1.3B
P/E (next 12 months, estimated)-5.2
52-week range$23.75 – $52.93
Dividend yieldNo dividend
Analyst consensusStrong Buy (15)
Average analyst price target$64.97 (+147%)
Valuation and fundamentals

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: 2026-11-05 · before open · EPS est -1.22
24-1125-0325-0525-0825-1126-0326-0526-08-1.190.00
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-05-0.99-1.19-20.4%
2026-05-07-0.71-0.42+40.7%
2026-03-10-0.67-0.72-6.8%
2025-11-06-0.73-0.71+3.0%
2025-08-07-0.77-0.75+2.6%
2025-05-08-0.74-0.68+8.7%
2025-03-11-0.70-0.57+18.6%
2024-11-07-0.52-0.50+3.9%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$20.0M–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–
Rating changes
Reiterated
2026-10-21 · Wells Fargo reiterated Overweight on RAPP
Reiterated
2026-10-21 · Guggenheim reiterated Buy on RAPP
Reiterated
2026-10-20 · HC Wainwright & Co. reiterated Buy on RAPP
Reiterated
2026-10-20 · BTIG reiterated Buy on RAPP
Initiated
2026-10-15 · UBS started covering RAPP at Buy
Initiated
2026-10-15 · Wolfe Research started covering RAPP at Outperform

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 12:05:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Beta 0.9 · Oct 21, 2026